Meet the people behind Kane Biotech.
President and Chief Executive Officer
Mark Ahrens-Townsend joined Kane Biotech in May 2015 as President and CEO. Mr. Ahrens-Townsend brings extensive expertise in leadership, strategic planning, and business development. He has spent 30+ years in the Technology, Engineering and Venture Capital industries. For the last 19 years Mr. Ahrens-Townsend has held senior executive roles, twice as President and CEO of two publicly traded technology companies, and has also served extensively on the boards and committees of several private and publicly held companies. Mr. Ahrens-Townsend holds B.Sc. (Engineering) and MBA (Finance) degrees from the University of Manitoba.
Chief Financial Officer
Ray Dupuis joined Kane Biotech as Chief Financial Officer in September 2017. Mr. Dupuis has more than 25 years of financial leadership experience across a broad range of industries including 15 years at a rapidly growing public biotechnology company and brings to the organization considerable financial acumen and strategic skills. Mr. Dupuis is a Chartered Professional Accountant (CPA, CGA) and possesses Bachelor of Science (Biology), Bachelor of Arts (Administrative Studies) and Master of Business Administration (Finance) degrees.
Vice President, Sales
Grant Humphrey joined Kane Biotech as Vice President, Sales in July, 2016. Mr. Humphrey is an accomplished, award winning sales professional. An entrepreneur, he has invented, patented and developed a product from conception to market that is still being sold today. He possesses a hunter-like mentality that allows him to meet and exceed sales targets, and his ability to build relationships leads to successful partnerships across many industries both domestically and internationally. He has experiences in veterinary and human healthcare, B2B and B2G marketing programs.
Senior Research Scientist
Nanda Yakandawala joined Kane Biotech in 2003 and leads the Company’s research efforts. Originally graduating with his B.Sc. from the University of Peradeniya in Sri Lanka, Dr. Yakandawala completed his M.Sc. in biotechnology at the University of Adelaide in Australia followed by his Ph.D. in molecular biology at the Swiss Federal Institute in Zurich. Dr. Yakandawala is a recognized expert in biofilms and is widely published in his field.
Wendy Nachtigall joined Kane Biotech in October 2015 as Director, Retail. With 15+ years in the marketing communications industry, Ms. Nachtigall brings a wealth of knowledge and expertise in planning, implementing and evaluating strategic marketing and communications initiatives in the consumer, institutional and B2B sectors, including new product and service introductions, brand development strategies and growth of business. Ms. Nachtigall has a proven track record in project management, as well as developing and maintaining long-term business relationships.
Director, Regulatory and Quality Control
Andrea Gordon joined Kane Biotech as Director, Regulatory and Quality Control in July 2015. Ms. Gordon has been working in the field of quality assurance and regulatory compliance for over 15 years in a variety of disciplines including telecommunications, medical devices, and devices intended for use in explosive atmospheres. Ms. Gordon holds a Bachelor of Science (Computer Engineering) and a Certificate in Quality Management from the University of Manitoba.
Board of Directors
Mr. Philip Renaud
Mr. Renaud is Managing Director of Church Advisors, a European investment advisory firm involved in private financings. A graduate of Franklin College of Switzerland with a Bachelor of Arts in international financial management, Mr. Renaud has been instrumental in securing many private equity financings and has an extensive European and North American network. He is a director of a number of publicly traded companies including Yorbeau Resources Inc., Diagnos Inc., Sierra Metals Inc., and is on the advisory board of Dundee Sarea.
Mr. Mark Ahrens-Townsend
Mr. Mark Ahrens-Townsend joined Kane Biotech in May 2015 as President and CEO. Mr. Ahrens-Townsend brings extensive expertise in leadership, strategic planning, and business development. He has spent 30+ years in the technology, engineering and venture capital industries. For the last 19 years Mr. Ahrens-Townsend has held senior executive roles, twice as President and CEO of two publicly traded technology companies, and has also served extensively on the boards and committees of several private and publicly held companies.
Mr. Mark Nawacki
Mr. Mark Nawacki is the president and CEO of Searchlight Pharma. Prior to this, Mr. Nawacki served as Executive Vice President, Business and Corporate Development of Paladin Labs, a leading Canadian specialty pharmaceutical company, from 2003 – 2014. Mr. Nawacki holds a BA in International Relations and Russian and East European Studies from the University of Toronto (Trinity), MBA also from the University of Toronto, and is a Canadian-designated CPA. He is a past member of the Board of Trustees of the Licensing Executive Society (USA & Canada) and is a former President and Board Member of the Canadian Healthcare Licensing Association. He also currently sits on the Board of the Montreal Bach Festival and The Sacred Heart School of Montreal.
Mr. Edwards is the founder and President of VetRx, a Montreal-based technology company specializing in data collection, cleansing, marketing and pharmaceutical compliance for the veterinary industry. Mr. Edwards holds a Bachelor’s degree (Finance) from l’Université de Sherbrooke and an MBA from Concordia University.
Rivka (Rashieda) Gluck
Ms. Gluck currently serves as Senior Vice President of Global Clinical Operations at Aurinia Pharmaceuticals Inc. since February 2018 and has also served as its Vice President of Clinical Operations since January 1, 2016. She previously served as Vice President of Clinical Operations at Qu Biologics Inc., where she led the clinical development of their platform immunotherapeutic treatments. Prior to that, Ms. Gluck served as Vice President and Head of Global Clinical Operations at Vifor Pharmaceuticals, based in Zurich Switzerland post acquisition of Aspreva Pharmaceuticals where she was Vice President of Clinical Operations. In her career, Ms. Gluck served in increasingly senior positions at major pharmaceutical companies including Novartis, Organon, and GSK. Ms. Gluck holds a B.Sc. in Nursing from the University of British Columbia.
Dr. Sarah Prichard
Dr. Sarah Prichard has served as global Vice President of R&D, Renal Medical and Therapeutic Area Leader, Baxter Healthcare from 2005-2014. Prior to this role, she was on faculty at McGill University from 1979-2005. Dr. Prichard received her MD from Queens University and trained in Internal Medicine and Nephrology at McGill University. While at McGill, she served as Associate Dean of Medicine, Chief of Service for the Department of Medicine, Senior Physician and Director of Peritoneal Dialysis at the Royal Victoria Hospital.